224 related articles for article (PubMed ID: 26089644)
1. A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas.
Zhang Y; Sun X; Huang M; Ke Y; Wang J; Liu X
Drug Des Devel Ther; 2015; 9():2947-59. PubMed ID: 26089644
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells.
Sun XL; Xu ZM; Ke YQ; Hu CC; Wang SY; Ling GQ; Yan ZJ; Liu YJ; Song ZH; Jiang XD; Xu RX
Cancer Lett; 2011 Dec; 312(2):168-77. PubMed ID: 21924825
[TBL] [Abstract][Full Text] [Related]
3. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
Nakamizo A; Marini F; Amano T; Khan A; Studeny M; Gumin J; Chen J; Hentschel S; Vecil G; Dembinski J; Andreeff M; Lang FF
Cancer Res; 2005 Apr; 65(8):3307-18. PubMed ID: 15833864
[TBL] [Abstract][Full Text] [Related]
4. Human mesenchymal stem cells-like cells as cellular vehicles for delivery of immunotoxin in vitro.
Hu CC; Ke YQ; Sun XL; Jiang XD; Xu RX; Lv J; Wang YS; Cai YQ; Qin LS; Zou YX
Biotechnol Lett; 2009 Feb; 31(2):181-9. PubMed ID: 18923908
[TBL] [Abstract][Full Text] [Related]
5. Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins.
Loya J; Zhang C; Cox E; Achrol AS; Kesari S
CNS Oncol; 2019 Nov; 8(3):CNS38. PubMed ID: 31747788
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas.
Hata N; Shinojima N; Gumin J; Yong R; Marini F; Andreeff M; Lang FF
Neurosurgery; 2010 Jan; 66(1):144-56; discussion 156-7. PubMed ID: 20023545
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of glioblastoma cell invasion by hsa-miR-145-5p and hsa-miR-31-5p co-overexpression in human mesenchymal stem cells.
Kurogi R; Nakamizo A; Suzuki SO; Mizoguchi M; Yoshimoto K; Amano T; Amemiya T; Takagishi S; Iihara K
J Neurosurg; 2018 Mar; 130(1):44-55. PubMed ID: 29521593
[TBL] [Abstract][Full Text] [Related]
8. Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model.
Hu CC; Ji HM; Chen SL; Zhang HW; Wang BQ; Zhou LY; Zhang ZP; Sun XL; Chen ZZ; Cai YQ; Qin LS; Lu L; Jiang XD; Xu RX; Ke YQ
Int J Cancer; 2010 Nov; 127(9):2222-9. PubMed ID: 20127864
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.
Rand RW; Kreitman RJ; Patronas N; Varricchio F; Pastan I; Puri RK
Clin Cancer Res; 2000 Jun; 6(6):2157-65. PubMed ID: 10873064
[TBL] [Abstract][Full Text] [Related]
10. EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma.
Huang L; He H; Wang K; Ma X; Chen X; Chen W; Wang X; Jiang X; Feng M
Biomed Pharmacother; 2022 Nov; 155():113659. PubMed ID: 36095959
[TBL] [Abstract][Full Text] [Related]
11. Cintredekin besudotox in treatment of malignant glioma.
Mut M; Sherman JH; Shaffrey ME; Schiff D
Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxins directed at interleukin-4 receptors as therapy for human brain tumors.
Puri RK
Methods Mol Biol; 2001; 166():155-76. PubMed ID: 11217365
[No Abstract] [Full Text] [Related]
13. A Novel Bispecific Immunotoxin Delivered by Human Bone Marrow-Derived Mesenchymal Stem Cells to Target Blood Vessels and Vasculogenic Mimicry of Malignant Gliomas [Retraction].
Drug Des Devel Ther; 2021; 15():3733-3734. PubMed ID: 34511882
[TBL] [Abstract][Full Text] [Related]
14. Convection-enhanced delivery in clinical trials.
Hall WA; Rustamzadeh E; Asher AL
Neurosurg Focus; 2003 Feb; 14(2):e2. PubMed ID: 15727423
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma.
Balyasnikova IV; Ferguson SD; Sengupta S; Han Y; Lesniak MS
PLoS One; 2010 Mar; 5(3):e9750. PubMed ID: 20305783
[TBL] [Abstract][Full Text] [Related]
16. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
17. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
Shimamura T; Husain SR; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016
[TBL] [Abstract][Full Text] [Related]
18. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
19. Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme.
Hjortland GO; Garman-Vik SS; Juell S; Olsen OE; Hirschberg H; Fodstad O; Engebraaten O
J Neurosurg; 2004 Feb; 100(2):320-7. PubMed ID: 15086240
[TBL] [Abstract][Full Text] [Related]
20. TNF-α respecifies human mesenchymal stem cells to a neural fate and promotes migration toward experimental glioma.
Egea V; von Baumgarten L; Schichor C; Berninger B; Popp T; Neth P; Goldbrunner R; Kienast Y; Winkler F; Jochum M; Ries C
Cell Death Differ; 2011 May; 18(5):853-63. PubMed ID: 21127499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
